OTEZLA
What it isPDE4 inhibitor that raises intracellular cAMP; plaque psoriasis, psoriatic arthritis, and Behcet oral ulcers.
Why this oneIt is oral and requires neither routine laboratory monitoring nor tuberculosis screening, unlike biologic therapy.
What limits itEarly diarrhea, nausea, and weight loss can end treatment; depression is labeled, and efficacy trails biologics.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Psoriatic arthritis | adults | 5-day titration (Days 1-5) | 30 mg BID | 30 mg BID |
| Plaque psoriasis | adults | 5-day titration (Days 1-5) | 30 mg BID | 30 mg BID |
| Behçet's disease | adults | 5-day titration (Days 1-5) | 30 mg BID | 30 mg BID |
| Psoriatic arthritis or moderate-severe plaque psoriasis | peds ≥6 y, ≥50 kg | titration | 30 mg BID | 30 mg BID |
| Psoriatic arthritis or moderate-severe plaque psoriasis | peds ≥6 y, 20-<50 kg | titration | 20 mg BID | 20 mg BID |
Titration 5-day up-titration (Days 1-5) to maintenance dose to reduce GI symptoms.
Renal Severe renal impairment: reduce to 30 mg QD (adults & peds ≥50 kg) or 20 mg QD (peds 20-<50 kg); titrate using AM schedule only, skip afternoon doses.
Hepatic No adjustment needed
Pregnancy May increase risk of fetal loss (animal embryo-fetal death); advise pregnant women of the risk.
Lactation No human data; detected in animal milk.
NO BOXED WARNINGS
Principal riskDiarrhea and weight loss; depression is labeled
Cost, est. cash$1,000–$15,000+/month
Generic entry2028 est.
Legacy pregnancy categoryC
Defining liabilitySerious infection, cytopenias, hepatic injury and malignancy risk require laboratory and clinical monitoring.

Open Apremilast in the interactive console ↗
